Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARM008
- Development stage
- Preclinical
- Lead developer
- TriArm Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ARM008 is an investigational dual-targeting chimeric antigen receptor T-cell (CAR-T) therapy developed by TriArm Therapeutics. It is designed to target both CD19 and B-cell maturation antigen (BCMA) for the treatment of autoimmune diseases. ARM008 is manufactured using TriArm's proprietary Fast-in-Time (FIT™) non-viral gene transfer platform, which is designed to reduce manufacturing time and cost while producing potent and persistent CAR-T cells. The therapy is currently in preclinical development.
- Other names
- FIT-CD19/BCMA CAR-TFIT-CD19/BCMA CAR-T cells
02
Targets
Beyond the preview
Go deeper on ARM008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARM008.
Work on ARM008? Claim this page to correct or add information. Claim this page